Compare WSO & ILMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | WSO | ILMN |
|---|---|---|
| Founded | 1945 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.4B | 18.9B |
| IPO Year | N/A | 2000 |
| Metric | WSO | ILMN |
|---|---|---|
| Price | $348.13 | $128.90 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 8 | 15 |
| Target Price | ★ $435.00 | $114.93 |
| AVG Volume (30 Days) | 381.1K | ★ 1.5M |
| Earning Date | 10-29-2025 | 10-30-2025 |
| Dividend Yield | ★ 3.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 12.87 | 4.46 |
| Revenue | ★ $7,414,495,000.00 | $4,288,000,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $4.21 | $2.08 |
| P/E Ratio | ★ $27.01 | $28.91 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $323.05 | $68.70 |
| 52 Week High | $535.40 | $153.06 |
| Indicator | WSO | ILMN |
|---|---|---|
| Relative Strength Index (RSI) | 48.80 | 66.70 |
| Support Level | $337.73 | $124.27 |
| Resistance Level | $356.99 | $129.72 |
| Average True Range (ATR) | 10.38 | 3.90 |
| MACD | 2.70 | -0.41 |
| Stochastic Oscillator | 73.88 | 77.82 |
Watsco is the largest heating, ventilation, air conditioning, and refrigeration products distributor in North America. The company primarily operates in the United States (90% of revenue), with significant exposure in the Sun Belt states. Watsco also has operations in Canada (5% of sales) and Latin America (5% of sales). The company's customer base consists of more than 125,000 contractors that serve the replacement and new construction HVACR markets for residential and light commercial applications.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (9% of 2024 sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.